Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience
The Journal of Clinical Endocrinology & Metabolism · 2023
DOI: 10.1210/clinem/dgad378 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Mônica Gadelha und 8 weiteren Autor:innen. Beteiligte Einrichtung: Neuroendocrinology Research Center, Endocrinology Section, Medical School and Hospital Universitário Clementino Fraga Filho, Universidade Federal do …. Hauptthemen laut MEDLINE: Acromegaly, Human Growth Hormone, Adenoma. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Pharma, Recordati, Mudskipper Business Ltd.
Abstract (Originalsprache)
Context
Acromegaly is a rare, chronic, debilitating disorder caused by prolonged hypersecretion of growth hormone (GH) and overproduction of insulin-like growth factor I (IGF-I). Medical therapies, including the somatostatin receptor ligand (SRL) pasireotide, are frequently used to restore biochemical control.
Objective
As patients often receive therapy over prolonged periods, long-term data from real-life settings are needed.
Methods
A retrospective analysis was performed using a prospectively maintained database of all patients with acromegaly from our primary care center who were enrolled in clinical studies with pasireotide (first visit November 2008). The main outcome measures were safety and biochemical control (age-adjusted IGF-I ≤ upper limit of normal).
Results
Patients (n = 50) entered 4 parental studies and 30 continued in the rollover; at data cutoff (June 2022), 27 were still receiving pasireotide. Overall, median (range) exposure was 58 (3-137) months. Normal IGF-I was achieved in 54%, and acromegaly symptoms and quality of life were improved with treatment. No predictors of pasireotide response were identified; however, controlled patients had smaller tumors and lower GH at baseline. Tumor volume reduction occurred in 63% of evaluable patients (n = 10/16). Most patients presented hyperglycemic events, including 63.2% of patients with normal glucose before treatment. Older patients and those with higher IGF-I, glucose, and HbA1c at baseline had higher glucose and HbA1c during pasireotide treatment.
Conclusion
Pasireotide provided clinical benefit and was well tolerated for more than 11 years of treatment in acromegaly patients, most of whom were resistant to first-generation SRLs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuroendocrinology Research Center, Endocrinology Section, Medical School and Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-913, Brazil.
ORCID-Profile: Mônica Gadelha
Förderung
- Novartis Pharma
- Recordati
- Mudskipper Business Ltd
Zitieren
APA
Gadelha, M., Marques, N. V., Fialho, C., Scaf, C., Lamback, E., Antunes, X., Santos, E., Magalhães, J., & Wildemberg, L. E. (2023). Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad378
Vancouver
Gadelha M, Marques NV, Fialho C, Scaf C, Lamback E, Antunes X, et al. Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgad378
BibTeX
@article{Gadelha2023,
author = {Gadelha, Mônica and Marques, Nelma Verônica and Fialho, Christhiane and Scaf, Cristiane and Lamback, Elisa and Antunes, Ximene and Santos, Erica and Magalhães, Jaqueline and Wildemberg, Luiz Eduardo},
title = {Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
doi = {10.1210/clinem/dgad378}
}
EUVIMED